Drugs from a class called tyrosine kinase inhibitors have become standard treatments for some cancers, but the improved survival of patients taking these medicines introduces a new problem. As patients live longer, many decide they no longer want to live with the side effects, so they try switching to more tolerable therapies. Enliven Therapeutics is developing new tyrosine kinase inhibitors […]
